The short version of nuclear receptor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-07-18. Anything still debated is marked as such rather than presented as settled.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
== History == In 1920, a conference held during the 1st World Scout Jamboree at Olympia, London agreed to create a Boy Scouts international bureau. An office was established at 25 Buckingham Palace Road, London and The Boy Scouts Association of the United Kingdom International Commissioner, Hubert S. Martin, was appointed honorary director. The bureau's principal task was to co-ordinate discussions and prepare a second international conference in Paris in 1922. At the 1922 Paris conference, The International Conference of the Boy Scout Movement and its committee were constituted and took over the bureau in London. In 1961, the organisation's conference reconstituted the organisation under the name World Organization of the Scout Movement (WOSM). Its International Conference of the Boy Scout Movement became WOSM's World Scout Conference ("conference"), its Boy Scouts International Committee became WOSM's World Scout Committee ("committee") and its Boy Scouts International Bureau became WOSM's World Scout Bureau ("bureau").
=== Learning and memory === The first learning and memory mutants (dunce, rutabaga, etc.) were isolated by William "Chip" Quinn while in Benzer's lab, and were eventually shown to encode components of an intracellular signaling pathway involving cyclic AMP, protein kinase A, and a transcription factor known as CREB. These molecules were shown to be also involved in synaptic plasticity in Aplysia and mammals. The initial report by William Quinn et al. described a basic conditioned preference assay. Over the next decade, the assay evolved into the classical olfactory conditioning paradigm in the T-maze: ~100 flies in a vial are connected to a short hallway that splits in two directions, a T-maze. On either end of the T-maze are two odors that are initially neutral, i.e. flies do not show preference for one odor or the other. The assay involves counting the number of flies in each side of the T-maze corridor. Before training half of the flies, on average, will before in each end. During training, the flies also encounter a stimulus in one of the two ends, typically either a sugar reward or an electric shock. After training, flies will show a preference for one odor or another. The two odors are referred to as the conditioned stimulus (CS), and the reward is the unconditioned stimulus (US). The T-maze assay was used to show where in the fly brain the association is made between the unconditioned stimulus and the conditioned stimulus. Olfactory sensory information is carried by antennal lobe projection neurons to the Kenyon cells of the mushroom body of the fly brain.
In December 2000, Dutch journalist Marjon van Royen found that "because the chemical is sprayed in Colombia from planes on inhabited areas, there have been consistent health complaints [in humans]. Burning eyes, dizziness and respiratory problems being most frequently reported." In some areas, 80 percent of the children of the indigenous community fell sick with skin rashes, fever, diarrhoea and eye infections. Because the glyphosate is sprayed from the air, there is a much higher chance of human error when spraying suspected illegal coca plantations. In many cases the wrong fields are sprayed, resulting in not only a total loss of the farmer's crop- but the loss of that field altogether as nothing will grow where the herbicide has been sprayed. Though official documentation of the health effects of glyphosate spraying in Colombia are virtually non-existent, neighbouring Ecuador has conducted studies to determine the cause of mysterious illnesses amongst people living along the border of Colombia and has since demanded that no aerial sprayings occur within 10 km of the border because of the damages caused to the people, animals and environment in that area. In 2015, Colombia announced a ban on using glyphosate in these programs due to concerns about human toxicity of the chemical.
Sources: en.wikipedia.org
=== Unmelted sample analysis === Methods to analyze the microbe populations of colder, unmelted ice samples (cold enough to prevent brine drainage) under microscopes were developed by designing specialized equipment. Epifluorescence microscopes that can operate at subzero temperatures allowed researchers to observe undisturbed brine pool microbe populations with the addition of DAPI (DNA staining 4', 6-diamidino-2-phenylindole) mixed into an adequately salty and cold brine solution to highlight non-autofluorescing microbes. Alternatively, a microscope with a cold stage, commonly used to study glacial ice, may also be used to study unmelted sea ice with the right modifications. Other stains such as Alcian Blue (stains extracellular polysaccharide substances) and CTC (stains oxygen-respiring bacteria, 5-cyano-2,3-ditolyl tetrazolium) have also been used. Alcian Blue stains have revealed that extracellular polymeric substances (EPS) are ubiquitous throughout brine pools found in sea ice, even without any microbes visible in the brine pool. Some EPS originates from seawater before freezing but is also produced in copious amounts within algal bands and by bacteria to a lesser extent but throughout the entirety of the sea ice. CTC stains have indicated greater percentages of microbial activity within the sea ice when compared to the seawater below it, especially bacteria associated with particulate matter.
Murphree developing centrifuges, and Arthur Compton responsible for theoretical studies and design. On 23 April 1942, Met Lab scientists discussed seven possible ways to extract plutonium from irradiated uranium, and decided to pursue investigation of all seven. On 17 June, the first batch of uranium nitrate hexahydrate (UNH) was undergoing neutron bombardment in the Washington University in St. Louis cyclotron. On 27 July, the irradiated UNH was ready for Glenn T. Seaborg's team. On 20 August, using ultramicrochemistry techniques, they successfully extracted plutonium. In May 1942, Gertrude Scharff Goldhaber at Brookhaven National Laboratory reports for the first the emission of multiple neutrons during spontaneous fission of uranium. Her research was kept a secret. In April 1939, creating a chain reaction in natural uranium became the goal of Fermi and Szilard, as opposed to isotope separation. Their first efforts involved five hundred pounds of uranium oxide from the Eldorado Radium Corporation. Packed into fifty-two cans two inches in diameter and two feet long in a tank of manganese solution, they were able to confirm more neutrons were emitted than absorbed. However, the hydrogen within the water absorbed the slow neutrons necessary for fission. Carbon in the form of graphite, was then considered, because of its smaller capture cross section. In April 1940, Fermi was able to confirm carbon's potential for a slow-neutron chain reaction, after receiving National Carbon Company's graphite bricks at their Pupin Laboratories.
== Career and research == Bewley is a senior investigator and Chief of the Laboratory of Bioorganic Chemistry at the National Institute of Diabetes and Digestive and Kidney Diseases. Her scientific focus includes chemical biology, molecular pharmacology, structural biology, microbiology, and infectious diseases. Bewley researches secondary metabolites and basic principles involved in protein-carbohydrate interactions and how these can be exploited to engineer therapeutics. She also designs and synthesizes small molecules and peptides that block, or can be used to probe the events that lead to viral entry. Her scientific focus includes chemical biology, molecular pharmacology, structural biology, microbiology, and infectious diseases.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.